Mersana Therapeutics, Inc. (MRSN)

NASDAQ: MRSN · Real-Time Price · USD
7.75
-0.36 (-4.44%)
At close: Aug 22, 2025, 4:00 PM
7.75
0.00 (0.00%)
After-hours: Aug 22, 2025, 4:00 PM EDT
-4.44%
Market Cap38.63M
Revenue (ttm)34.77M
Net Income (ttm)-74.04M
Shares Out 4.99M
EPS (ttm)-14.94
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume71,577
Open8.16
Previous Close8.11
Day's Range7.71 - 8.19
52-Week Range5.21 - 70.75
Beta0.82
AnalystsStrong Buy
Price Target63.67 (+722.61%)
Earnings DateAug 13, 2025

About MRSN

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc.... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 28, 2017
Employees 102
Stock Exchange NASDAQ
Ticker Symbol MRSN
Full Company Profile

Financial Performance

In 2024, Mersana Therapeutics's revenue was $40.50 million, an increase of 9.88% compared to the previous year's $36.86 million. Losses were -$69.19 million, -59.69% less than in 2023.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for MRSN stock is "Strong Buy." The 12-month stock price target is $63.67, which is an increase of 722.61% from the latest price.

Price Target
$63.67
(722.61% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Brian C. DeSchuytner - Senior VP, CFO & COO Jason Fredette - Senior Vice Pres...

9 days ago - Seeking Alpha

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) ...

9 days ago - GlobeNewsWire

Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025

CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) ...

16 days ago - GlobeNewsWire

Mersana Therapeutics Announces 1-for-25 Reverse Stock Split

CAMBRIDGE, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) ...

4 weeks ago - GlobeNewsWire

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) ...

2 months ago - GlobeNewsWire

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) t...

3 months ago - GlobeNewsWire

Mersana Therapeutics, Inc. (MRSN) Q1 2025 Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Conference Call May 15, 2025 8:00 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations & Corporate Communica...

3 months ago - Seeking Alpha

CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ: MRSN), please note that there was a transcription error in the last cell of the first table. The Median...

3 months ago - GlobeNewsWire

Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (A...

3 months ago - GlobeNewsWire

Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (A...

3 months ago - GlobeNewsWire

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting

CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-...

4 months ago - GlobeNewsWire

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

5 months ago - GlobeNewsWire

Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-...

5 months ago - GlobeNewsWire

Mersana Therapeutics, Inc. (MRSN) Q4 2024 Earnings Call Transcript

Mersana Therapeutics, Inc. (MRSN) Q4 2024 Earnings Call Transcript

6 months ago - Seeking Alpha

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-...

6 months ago - GlobeNewsWire

Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

6 months ago - GlobeNewsWire

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

7 months ago - GlobeNewsWire

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?

On Friday, Mersana Therapeutics Inc. MRSN released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin.

8 months ago - Benzinga

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ET Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ET

8 months ago - GlobeNewsWire

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

- Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile - Promising clinical activity observed in patients with triple-negative breast cancer ...

8 months ago - GlobeNewsWire

Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable

Mersana Therapeutics is developing novel antibody-drug conjugates targeting a heretofore untapped immune checkpoint, as well as HER2 from another angle. The company has an operational runway of 6-7 qu...

8 months ago - Seeking Alpha

Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Jason Fredette - SVP, IR Martin Huber - President & CEO Mohan Bala - SVP, C...

10 months ago - Seeking Alpha

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

CAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

10 months ago - GlobeNewsWire

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d...

10 months ago - GlobeNewsWire

Mersana Therapeutics, Inc. (MRSN) Q2 2024 Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Martin Huber - President & CEO Brian DeSchuytner - CFO & COO Jason Fredette -...

1 year ago - Seeking Alpha